Flavonoller, Kardiyovasküler/Serebrovasküler Hastalıklar ve Kanser

Flavonoidler, polifenollerin en geniş ve önemli sınıflarından birisidir. Bu moleküller, bitkisel orjinli pek çok besinde bulunurlar. Flavonoidler moleküler yapılarına göre 6 gruba ayrılırlar. Flavonoid grup içerisinde en aktif bileşikler olan flavonoller en geniş biyolojik aktivite gösteren gruptur. Flavonoller ile ilgili yapılan in vivo ve invitro çalışmalarda, antioksidan, antiinflamatuvar, antihipertansif, antiaterojenik, antikarsinojenik, antiproliferatif pek çok işlevleri olduğu gösterilmiştir. Flavonoller ile kanser ve kardiyovasküler/serebrovasküler hastalıklar arasındaki ilişkinin incelendiği çalışmalarda da koruyucu etkinlikleri gösterilmiştir. Bu derleme yazıda flavonoller, kimyasal yapıları, kanser ve kalp damar hastalıkları ile ilgili yapılan çalışma sonuçları değerlendirilmiştir

Flavonols, Cardiovascular/Cerebrovascular Diseases and Cancer

Flavonoids are one of the largest and most important class of polyphenols. Many foods with plant origin include these compounds. Flavonoids are classified 6 groups according to their molecular structures. Flavonols are the most active compounds that have wide biological activity in the flavonoid group. In vivo and in vitro studies on flavonols have shown that they have many functions such as antioxidant, antiinflammatory, antihypertensive, antiatherogenic, anticarcinogenic and antiproliferative functions. Protective activitiesof flavanols have also been demonstrated in studies investigating the relationship between flavonols and cancer and cardiovascular/cerebrovascular diseases. In this review article, the results of the studies on flavonols, their chemical structures and their effects on cancer and cardiovascular diseases has been evaluated

Kaynakça

1. Wildman RE. Handbook of Nutraceuticals and Functional Foods. Washington DC, 2001.

2. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, and human health: Epidemiological evidence. J Med Food 2005;8(3):281-290.

3. Corradini E, Foglia P, Giansanti P, Gubbiotti R, Samperi R, Lagana. A Flavonoids: chemical properties and analytical methodologies of identification and quantitation in foods and plants. Nat Prod Res 2011;25(5):469-495.

4. Crozier A, Jaganathb B, Cliffordc M. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009;26:1001-1043.

5. Russo M, Spagnuolo C, Tedesco I, Bioltto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem Pharmacol 2012;83: 6-15.

6. Perez-Vizcaino F, Duarte J. Flavonols and cardiovascular disease. Mol Aspects of Med 2010;31:478-494.

7. Davalos A, Castilla P, Gomez-Cordoves C, Bartolome B. Quercetin is bioavailable from a single ingestion of grape juice. Int J Food Sci Nutr 2006;57:391-398.

8. Kahraman A, Serteser M, Köken T. Flavonoidler. Kocatepe Tıp Dergisi 2002;3:01-08.

9. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo, M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008;16:2081-2087.

10. Hollman PC, Geelen A, Kromhout D. Dietary flavonol intake may lower stroke risk in men and women. J Nutr 2010;140:600-604.

11. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007;137:2405-2411.

12. Egert S, Boesch-Saadatmandi, C, Wolffram S, Rimbach G, Muller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010;140:278-284.

13. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 2003;57:904- 908.

14. Lin J, Rexrode KM, Hu F, Albert CM, Chae CU, Rimm EB, et al. Dietary intakes of flavonols and flavones and coronary hearth disease in US women. Am J Epidemiol 2007;165:1305-1313.

15. Keli SO, Hertog MGL, Feskens EJM, Kromhout D. Flavonoids, antioxidant vitamins and risk of stroke. The Zutphen Study. Arch Intern Med 1996;156:637-642.

16. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliövaara M, Reunanen A, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002;76:560-568.

17. Hirvonen T, Virtamo J, Korhonen P,Albanes D, Pietinen P. Intake of flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. Stroke 2000;31:2301-2306.

18. Yochum L, Kushi LH, Meyer K, Aaron F. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol 1999;149:943-949.

19. Christian H, Keen CL, Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J 2010;31:2583-2592.

20. Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008;56: 6185-6205.

21. Yao H, Xu W, Shi X, Zhang Z. Dietary flavonoids as cancer prevention agents. J Environ Sci Health C 2011;29:1-31.

22. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000;92:154-160.

23. Theodoratou E, Kyle J, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, et al. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2007;16:684-693.

24. Rossi M, Negri E, Talamini R, Bosetti C, Parpinel M, Gnagnarella P et al. Flavonoids and colorectal cancer in Italy. Cancer Epidemiol Biomarkers Prev 2006;15:1555- 1558.

25. Bosetti C, Spertini L, Parpinel M, Gnagnarella P, Lagiou P, Negri E, et al. Flavonoids and breast cancer risk in Italy. Cancer Epidemiol Biomarkers Prev 2005;14:805-808.

26. Fink BN, Steck SE, Wolff MSBritton JA, Kabat GC, Schroeder JC, et al. Dietary flavonoid intake and breast cancer risk among women on Long Island. Am J Epidemiol 2007;165:514-523.

27. Rossi M, Negri E, Lagiou P, Talamini R, Dal Maso L, Montella M, et al. Flavonoids and ovarian cancer risk: a case-control study in Italy. Int J Cancer 2008;123:895-898.

28. Frankenfeld CL, Cerhan JR, Cozen W, Davis S, Schenk M, Morton LM, et al. Dietary flavonoid intake and nonHodgking lymphoma risk. Am J Clin Nutr 2008;87:1439- 1445.

29. Knekt P, Jarvinen R, Seppanen R, Hellövaara M, Teppo L, Pukkala E, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997;146:223-230.

30. Hirvonen T, Virtamo J, Korhonen P, Albanes D, Pietinen P. Flavonol and flavone intake and the risk of cancer in male smokers (Finland). Cancer Causes Control 2001;12:789- 796.

31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.

32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.

33. Gee JM, Hara H, Johnson IT. Supression of intestinal crypt cell proliferation and aberrant crypt foci by dietary quercetin in rats. Nutr Cancer 2002;43:193-201.

34. Warren CA, Paulhill KJ, Davidson LA, Lupton JR, Taddeo SS, Hong MY, et al. Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis. J Nutr 2009;139:101-105.

35. Goldbohm RA, Hertog MGL, Brants HAM, van Poppl G, van den Brandt PA. Consumption of black tea and cancer risk: A prospective cohort study. J Natl Cancer Inst 1996;88:93-100.

36. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary flavonoids and cancer risk in the Zutphen Elderly Study. Nutr Cancer 1994;22:175-184.

37. Kyle JA, Sharp L, Little J, Duthie GG, McNeill G. Dietary flavonoid intake and colorectal cancer: a case–control study. British J Nutr 2010;103:429-436.

38. Rossi M, Bosetti C, Negri E, Lagiou P, LaVecchia C. Flavonoids, proanthocyanidins and cancer risk: A Network of case- control studies from Italy. Nutr Cancer 2010;62(7):871-877.

Kaynak Göster

  • ISSN: 1300-3089
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1972

3.1b 2.4b